NO20022441L - Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse - Google Patents
Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disseInfo
- Publication number
- NO20022441L NO20022441L NO20022441A NO20022441A NO20022441L NO 20022441 L NO20022441 L NO 20022441L NO 20022441 A NO20022441 A NO 20022441A NO 20022441 A NO20022441 A NO 20022441A NO 20022441 L NO20022441 L NO 20022441L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- treating lupus
- preparations
- antibody affinity
- screening methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Oppfinnelsen tilveiebringer fremgangsmåter til påvisning av individer som er egnet for behandling av lupus og fremgangsmåter til overvåking av behandling basert på måling av antistoffaffiniteter, så vel som behandling av lupus basert på måling av antistoffaffiniteter. Behandlingen medfører administrering av et konjugat som omfatter et ikke-immunogent valensplattformmolekyl og minst to dobbelttrådete DNA epitoper, slik som DNA molekyler som binder til anti-dsDNA antistoffer fra pasienten.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16771699P | 1999-11-28 | 1999-11-28 | |
PCT/US2000/042307 WO2001041813A2 (en) | 1999-11-28 | 2000-11-28 | Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20022441D0 NO20022441D0 (no) | 2002-05-23 |
NO20022441L true NO20022441L (no) | 2002-07-09 |
Family
ID=22608518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20022441A NO20022441L (no) | 1999-11-28 | 2002-05-23 | Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse |
Country Status (11)
Country | Link |
---|---|
US (2) | US7081242B1 (no) |
EP (1) | EP1233791A2 (no) |
JP (1) | JP2003516526A (no) |
KR (1) | KR20020059808A (no) |
CN (2) | CN1399562A (no) |
AU (1) | AU783282C (no) |
CA (1) | CA2391944A1 (no) |
HK (1) | HK1045944A1 (no) |
MX (1) | MXPA02005236A (no) |
NO (1) | NO20022441L (no) |
WO (1) | WO2001041813A2 (no) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
CA2391944A1 (en) | 1999-11-28 | 2001-06-14 | Lajolla Pharmaceutical Company | Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
US20030114405A1 (en) * | 2001-08-13 | 2003-06-19 | Linnik Matthew D. | Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function |
AU2003303524A1 (en) * | 2002-12-27 | 2004-07-29 | La Jolla Pharmaceutical Company | Methods of improving health-related quality of life in individuals with systemic lupus erythematosus |
WO2004089422A2 (en) * | 2003-03-30 | 2004-10-21 | La Jolla Pharmaceutical Co. | Methods of treating and monitoring systemic lupus erythematosus in individuals |
US20060229270A1 (en) * | 2005-03-10 | 2006-10-12 | La Jolla Pharmaceutical Company | Methods of treating proteinuria by reducing double-stranded DNA antibodies |
US8492347B2 (en) * | 2007-10-17 | 2013-07-23 | The Regents Of The University Of California | Peptide for induction of immune tolerance as treatment for systemic lupus erythematosus |
CN102477079A (zh) * | 2010-11-24 | 2012-05-30 | 中国人民解放军军事医学科学院基础医学研究所 | 一种新型多肽在系统性红斑狼疮诊断中的应用 |
WO2012116210A2 (en) * | 2011-02-23 | 2012-08-30 | The Regents Of The University Of California | Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5370871A (en) | 1983-01-24 | 1994-12-06 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
US5126131A (en) | 1983-01-24 | 1992-06-30 | The Johns Hopkins University | Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates. |
US6022544A (en) | 1983-01-24 | 2000-02-08 | The John Hopkins University | Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry |
US5268454A (en) | 1991-02-08 | 1993-12-07 | La Jolla Pharmaceutical Company | Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier |
US5552391A (en) | 1990-01-16 | 1996-09-03 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
US5162515A (en) | 1990-01-16 | 1992-11-10 | La Jolla Pharmaceutical Company | Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus |
US5391785A (en) | 1990-01-16 | 1995-02-21 | La Jolla Pharmaceutial Company | Intermediates for providing functional groups on the 5' end of oligonucleotides |
AU8869291A (en) | 1990-10-04 | 1992-04-28 | University Of Virginia Alumni Patents Foundation, The | Primate erythrocyte bound monoclonal antibody heteropolymers |
JP2899111B2 (ja) | 1991-07-15 | 1999-06-02 | ラ ホヤ ファーマシューティカル カンパニー | オリゴヌクレオチドの5’末端へ官能基を提供するための修飾された亜リン酸中間体 |
EP0642798B1 (en) * | 1993-09-08 | 2007-04-18 | La Jolla Pharmaceutical Company | Chemically-defined non-polymeric valency platform molecules and conjugates thereof |
KR100361933B1 (ko) | 1993-09-08 | 2003-02-14 | 라 졸라 파마슈티칼 컴파니 | 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트 |
PT743856E (pt) | 1994-02-28 | 2003-12-31 | Univ Virginia | Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros |
US5874409A (en) | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
US5856464A (en) | 1995-06-07 | 1999-01-05 | Lajolla Pharmaceutical Company | Selective capping solution phase oligonucleotide synthesis |
CA2256449A1 (en) | 1996-06-06 | 1997-12-11 | Lajolla Pharmaceutical Company | Apl immunoreactive peptides, conjugates thereof and methods of treatment for apl antibody-mediated pathologies |
US5817752A (en) | 1996-06-06 | 1998-10-06 | La Jolla Pharmaceutical Company | Cyclic polypeptides comprising a thioether linkage and methods for their preparation |
DE69825576T2 (de) | 1997-04-11 | 2005-08-11 | Chiyoda Corp., Yokohama | Katalysator für die herstellung von synthesegas und verfahren zur herstellung von kohlenmonoxid |
EP2189791A3 (en) | 1998-02-04 | 2011-03-09 | Life Technologies Corporation | Microarrays and uses therefor |
PT1061954E (pt) | 1998-03-12 | 2004-10-29 | Nektar Therapeutics Al Corp | Derivados de poli(etileno glicol) com grupos reactivos proximos |
US6858210B1 (en) | 1998-06-09 | 2005-02-22 | La Jolla Pharmaceutical Co. | Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same |
IL141936A0 (en) | 1998-09-10 | 2002-03-10 | Univ Virginia | Antibodies to c3b(1) for delivery of diagnostic and therapeutic agents to cancer cells |
US6572856B1 (en) | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
JP2002531531A (ja) | 1998-12-09 | 2002-09-24 | ラ ホヤ ファーマシューティカル カンパニー | 循環している抗体を減少させるための方法および処方物 |
US20010010818A1 (en) | 1998-12-09 | 2001-08-02 | Engle Steven B. | Methods and formulations for reducing circulating antibodies |
US6458953B1 (en) | 1998-12-09 | 2002-10-01 | La Jolla Pharmaceutical Company | Valency platform molecules comprising carbamate linkages |
US6399578B1 (en) | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
CN1762990A (zh) | 1999-06-08 | 2006-04-26 | 拉卓拉药物公司 | 包含氨基氧基的化合价平台分子 |
CA2391944A1 (en) | 1999-11-28 | 2001-06-14 | Lajolla Pharmaceutical Company | Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
AU2593901A (en) | 1999-12-23 | 2001-07-03 | Elusys Therapeutics, Inc. | Therapeutic use of particles displaying pathogen-specific binding moieties |
EP1284752A4 (en) | 2000-04-26 | 2004-08-18 | Elusys Therapeutics Inc | BISPECIFIC MOLECULES AND USES THEREOF |
EP1292337A2 (en) | 2000-06-08 | 2003-03-19 | La Jolla Pharmaceutical | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
WO2002046208A2 (en) | 2000-11-01 | 2002-06-13 | Elusys Therapeutics, Inc. | Method of producing biospecific molecules by protein trans-splicing |
US20030077273A1 (en) | 2001-05-17 | 2003-04-24 | Linnik Matthew D. | Methods of treating antibody-mediated pathologies using agents which inhibit CD21 |
US20030114405A1 (en) | 2001-08-13 | 2003-06-19 | Linnik Matthew D. | Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function |
AU2003303524A1 (en) | 2002-12-27 | 2004-07-29 | La Jolla Pharmaceutical Company | Methods of improving health-related quality of life in individuals with systemic lupus erythematosus |
WO2004089422A2 (en) | 2003-03-30 | 2004-10-21 | La Jolla Pharmaceutical Co. | Methods of treating and monitoring systemic lupus erythematosus in individuals |
-
2000
- 2000-11-28 CA CA002391944A patent/CA2391944A1/en not_active Abandoned
- 2000-11-28 AU AU39702/01A patent/AU783282C/en not_active Ceased
- 2000-11-28 WO PCT/US2000/042307 patent/WO2001041813A2/en active IP Right Grant
- 2000-11-28 CN CN00816224A patent/CN1399562A/zh active Pending
- 2000-11-28 JP JP2001543157A patent/JP2003516526A/ja active Pending
- 2000-11-28 US US09/724,822 patent/US7081242B1/en not_active Expired - Fee Related
- 2000-11-28 CN CNA2008101656741A patent/CN101422614A/zh active Pending
- 2000-11-28 EP EP00992252A patent/EP1233791A2/en not_active Withdrawn
- 2000-11-28 KR KR1020027006803A patent/KR20020059808A/ko not_active Application Discontinuation
- 2000-11-28 MX MXPA02005236A patent/MXPA02005236A/es active IP Right Grant
-
2002
- 2002-05-23 NO NO20022441A patent/NO20022441L/no not_active Application Discontinuation
- 2002-10-10 HK HK02107393.6A patent/HK1045944A1/zh unknown
-
2005
- 2005-03-15 US US11/081,309 patent/US20060142229A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US7081242B1 (en) | 2006-07-25 |
HK1045944A1 (zh) | 2002-12-20 |
CN1399562A (zh) | 2003-02-26 |
NO20022441D0 (no) | 2002-05-23 |
EP1233791A2 (en) | 2002-08-28 |
WO2001041813A2 (en) | 2001-06-14 |
AU3970201A (en) | 2001-06-18 |
MXPA02005236A (es) | 2004-03-19 |
US20060142229A1 (en) | 2006-06-29 |
WO2001041813A3 (en) | 2002-01-03 |
CN101422614A (zh) | 2009-05-06 |
AU783282B2 (en) | 2005-10-06 |
CA2391944A1 (en) | 2001-06-14 |
JP2003516526A (ja) | 2003-05-13 |
AU783282C (en) | 2006-04-06 |
KR20020059808A (ko) | 2002-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0203567A2 (hu) | APRIL-receptor (BCMA) és alkalmazásai | |
DK1124568T3 (da) | Polyspecifikke bindingsmolekyler og anvendelser deraf | |
BRPI0416603A (pt) | anticorpo que se liga ao receptor interleucina-4 (il-4) humano | |
ATE222254T1 (de) | Verwendung von einem metalloporphyrinkonjugat für den nachweis biologischer verbindungen | |
ME00232B (me) | Antitijela za opgl | |
WO2004019878A3 (en) | Adzymes and uses thereof | |
NO20005694D0 (no) | Spesifikke bindingsmolekyler for scintigrafi, konjugater som inneholder disse og terapeutisk metode for behandling av angiogenese | |
WO2005014035A3 (en) | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest | |
NO995458D0 (no) | Humane 12-lignende reseptorproteiner, beslektede reagenser og metoder | |
DE602005021072D1 (de) | Adzyme und deren verwendungen | |
DE60140069D1 (de) | Funktion eines haptoglobin-hämoglobin-rezeptors und anwendungszwecke dafür | |
WO2003023057A3 (de) | Verfahren und diagnose-kit zur selektionierung und/oder zum qualitativen und/oder quantitativen nachweis von zellen | |
WO2005047860A3 (en) | Antibodies to alpha-synuclein | |
WO2002061129A3 (en) | Oligonucleotide identifiers | |
CY1111542T1 (el) | Αντισωματα εξουδετερωσης του rsv υπερυψηλης συγγενειας | |
WO2004106380A3 (en) | Human-anti-human cd3 binding molecules | |
NO20064866L (no) | IRTA-5 antistoffer og deres anvendelse | |
NO20022441L (no) | Fremgangsmåter for å behandle Lupus basert på antistoffaffinitet og screeningsmetoder, og preparater foranvendelse av disse | |
DK1692181T3 (da) | Leptinantagonist og fremgangsmåde til kvantitativ måling af leptin | |
WO2003106649A3 (en) | CONJUGATE TEST AND USES THEREOF | |
WO2004066933A3 (en) | Compositions and methods for treating cancer using igsf9 and liv-1 | |
ATE250966T1 (de) | Adsoptionschromatographie | |
WO2000002582A3 (en) | Treatment of celiac disease with interleukin-15 antagonists | |
DE59508137D1 (de) | Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine | |
CY1106349T1 (el) | Συστηματα ανιχνευσης ανοσοπροσδιορισμου ιικου αντιγονου ηπατιτιδας c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |